返回 Agendas
Medicine Development and Authorization: A Patient-Centered Approach
Session Chair(s)
Angelika Joos, MPharm
Executive Director, Science & Regulatory Policy
MSD, Belgium
A systematic and integrated framework to enable patient involvement during the development and life cycle of medicines and associated products is not yet really established. This session will provide examples how regulators in the US and Europe involve patients into the regulatory process and discuss how patients can bring their experience to the table.
Learning Objective : Identify important elements that could enhance outcomes through patient-centered research.
Speaker(s)
Patient Participation in FDA's Advisory Committees and Panels
Heidi Marchand, PharmD
Gilead Sciences, United States
Executive Director and Head of Global Regulatory Policy and Intelligence
Bringing Real-Life Experience into the Evaluation of Medicines
Martin Harvey Allchurch, LLM
European Medicines Agency, Netherlands
Head of International Affairs
Patient Perspective
Marc M. Boutin, JD
Novartis , Switzerland
Global Head of Patient Engagement and Advocacy
注册方法
Registration override should work.